Aslan, Mustafa Törehan2024-10-292024-10-292023979-888697714-1979-888697545-1https://hdl.handle.net/20.500.11776/12634Mesenchymal stem cells (MSC) therapy can overcome the damage caused by increased inflammation in cells and tissues that can occur due to many negative effects in newborns, increase their regeneration and perform various reparative functions (mainly with the paracrine effect), has been used in recent years to overcome very important morbidities and devastating problems [e.g., intraventricular hemorrhage (IVH), hypoxic-ischemic encephalopathy (HIE) and bronchopulmonary dysplasia (BPD)]. It has been suggested that the therapeutic effects of treatments with microvesicles and extracellular vesicles (EVs) containing exosomes, another secretory package of MSCs, which may be the other side of the coin and trending recently, may be better compared to MSCs. In the light of recent studies, stem cell therapy in neonatal diseases seems like a hope for the excitement of neonatologists. © 2023 Nova Science Publishers, Inc. All rights reserved.eninfo:eu-repo/semantics/closedAccessBronchopulmonary dysplasiaHypoxic-ischemic encephalopathyIntraventricular hemorrhageMesenchymal stem cell therapyNeonateStem cellBook Chapter4654732-s2.0-85159884891